New combo attack on eye cancer that spreads to the liver
NCT ID NCT04283890
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a combination of two immunotherapy drugs (ipilimumab and nivolumab) plus a chemotherapy drug (melphalan) given directly to the liver through a special procedure. It includes 83 adults with advanced uveal melanoma that has spread mainly to the liver. The goal is to see if this approach is safe and can slow or stop the cancer from growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ipilimumab, nivolumab, and melphalan
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced uveal melanoma that has spread to the liver, potentially improving control of the disease.
- What could go wrong
- This is an early-phase trial with only 83 participants, so results may not apply to everyone. The combination of immunotherapy and chemotherapy can cause serious side effects, and it is not yet known if it will improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA, METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Leiden University Medical Center
Leiden, South Holland, 2333 ZA, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.